Fundraising Fox

AgeX Therapeutics

Alameda, US · Founded 2017 · Alabama corporation

agexinc.com
Biotech

Founders & leadership

AgeX Therapeutics was founded in 2017 by Michael D. West.

MD
Michael D. WestPresident and CEO
RS
Russell SkibstedChief Financial Officer

Board

AK
Alfred KingsleyChairman
MH
Michael H. MulroyBoard director

Reported raises · per SEC filings

Form D private placements

$19M disclosed across 5 rounds · 2017–2019

$4.5MraisedMar 2019 · 17 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Annalisa JenkinsDirector
  • Michael D. WestExecutive Officer, Director
  • John F. MauldinDirector
  • Gregory BaileyDirector
  • Not Applicable BioTime, Inc.Promoter
  • Michael H. MulroyDirector
  • Russell SkibstedExecutive Officer
Offering amount
$5M
Amount sold
$4.5M
Proceeds to insiders
$900K
First sale
Mar 2019
Incorporated
Corporation, Delaware, 2017
Federal exemptions
06b
Full filing on SEC EDGAR ↗
$200KraisedAug 2018 · 1 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Michael D. WestExecutive Officer, Director
  • Not Applicable BioTime, Inc.Promoter
  • Russell SkibstedExecutive Officer
  • John MauldinDirector
  • Alfred KingsleyExecutive Officer, Director
  • Michael H. MulroyDirector
Amount sold
$200K
First sale
Aug 2018
Incorporated
Corporation, Delaware, 2017
Federal exemptions
06b
Full filing on SEC EDGAR ↗
$5MraisedJun 2018 · 1 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Alfred KingsleyExecutive Officer, Director
  • John MauldinDirector
  • Michael D. WestExecutive Officer, Director
  • Russell SkibstedExecutive Officer
  • Not Applicable BioTime, Inc.Promoter
  • Michael H. MulroyDirector
Offering amount
$5M
Amount sold
$5M
Minimum investment
$50K
Proceeds to insiders
$2.3M
First sale
Jun 2018
Incorporated
Corporation, Delaware, 2017
Federal exemptions
06b
Full filing on SEC EDGAR ↗
$462.5KraisedJan 2018 · 20 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Michael H. MulroyDirector
  • Russell SkibstedExecutive Officer
  • Not Applicable BioTime, Inc.Promoter
  • Alfred KingsleyExecutive Officer, Director
  • Michael D. WestExecutive Officer, Director
Offering amount
$1M
Amount sold
$462.5K
Minimum investment
$2.5K
Proceeds to insiders
$360K
First sale
Jan 2018
Incorporated
Corporation, Delaware, 2017
Federal exemptions
06b
Full filing on SEC EDGAR ↗
$8.8MraisedJul 2017 · 18 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Not Applicable BioTime, Inc.Promoter
  • Michael D. WestExecutive Officer, Director
  • Russell SkibstedExecutive Officer
  • Michael H. MulroyDirector
  • Alfred KingsleyDirector
Offering amount
$10M
Amount sold
$8.8M
Minimum investment
$50K
Proceeds to insiders
$3.6M
First sale
Jun 2017
Incorporated
Corporation, Delaware, 2017
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Non-dilutive funding · 2 SBIR/STTR awards

Federal grants — no equity taken
AgencyPhaseYearAmount
National Institutes of Health (NIH)National Institutes of HealthPhase ISTTR2023$341K
National Institutes of Health (NIH)National Institutes of HealthPhase I2018$225K

Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.

Frequently asked questions

Who founded AgeX Therapeutics?
AgeX Therapeutics was founded by Michael D. West in 2017.
How much funding has AgeX Therapeutics raised?
AgeX Therapeutics has disclosed $19M raised across 5 rounds.
Where is AgeX Therapeutics headquartered?
AgeX Therapeutics is headquartered in Alameda, US.